
Sign up to save your podcasts
Or


Since there are limited treatment options available for patients with refractory metastatic colorectal cancer (mCRC), the purpose of this global phase 3 cohort, called FRESCO-2, was to analyze the adverse events of a treatment. Tune into this segment to learn more about this study.
By ReachMD4.5
22 ratings
Since there are limited treatment options available for patients with refractory metastatic colorectal cancer (mCRC), the purpose of this global phase 3 cohort, called FRESCO-2, was to analyze the adverse events of a treatment. Tune into this segment to learn more about this study.

39 Listeners

10 Listeners

59 Listeners

1,142 Listeners

195 Listeners

45 Listeners

7 Listeners